AI Expo: 7 Free Things You Can Get Involved with at the Leading AI Event in Amsterdam
Arriving in Amsterdam on the 27-28 June, the second annual AI Expo Europe event will host 2 co-located events covering IoT and Blockchain, with 8,000 attendees expected to attend including CTO’s, CDO’s, Head’s of Innovation and Technology, IT Directors, Developers & Start-Up’s, OEM’s, Government, Automotive, Operators, Technology Providers, Investors, VCs and many more. The AI Expo will showcase the most cutting-edge technologies from more than 300 exhibitors and provide insight from over 300 speakers sharing their unparalleled industry knowledge and real-life experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180606006061/en/
A taster of the AI Expo Europe in Amsterdam (27-28th June). (Photo: Business Wire)
1. The exhibition and start-up incubator zone
The event will host a dedicated start-up incubator zone where you can see the latest AI & IoT technologies and innovations in action, in addition to the vast exhibition of 300+ companies who will be showcasing their products and services within the field of AI, IoT & Blockchain. Expect to see demos and booths from Microsoft, IBM, PTC, Kore, Hercules, Thales, Rutronik, Enterprise Ethereum Alliance, BPU Holdings, Start-up Amsterdam, ML6, Bottos, Ortec Data Science, Adani, NTR Labs, Prosper BI and many more. Start-ups within the incubator zone include Aiir Innovations, Botsquad, Mercury.AI, IoTify, Porter, 3D Universium, Zazu, 904 Labs, Innovation in Motion, Blockhearts, Mind Trace, Sightcorp, Cupenya, Effect.Ai, Sodaq, Amberscript, BrainCreators, Clockworks to name a few. In addition, attendees can join speakers from Aiir Innovations, Mercury.AI and BrainCreators within the AI Technologies track on day 2 (28th June) as they explore innovative artificial intelligence techniques.
2. 10 Conference Tracks covering AI, IoT and Blockchain
Your Free Expo Pass will provide access to 10 conference tracks; AI Technologies , Data Analytics for AI & IoT, Developing for the IoT , Privacy & Security , IoT Innovations & Technologies , ICOs & Token Investments, Blockchain for Business, Developing Blockchain Applications , Blockchain Technologies and Blockchain Strategies. Register for your free expo pass here.
3. Keynote Panel: IoT and AI data analytics for intelligent decision making
Taking place on the 27th June at 10.15am within the Data Analytics for AI & IoT conference track, the Chief Data Scientist at Southern Water, a Data Scientist from Monsanto, a Data Scientist from Marel Poulty and the CEO from the predictive intelligence firm Prosper BI will be identifying target-rich, high-value data that can be used to generate business intelligence, looking at the use of cloud analytics platforms to derive value from AI & IoT data, and discussing the barriers to widespread AI/IoT/Big Data value delivery and how these might be overcome.
4. Machine Learning and AI: Do’s and Don’ts in the online food provider industry
Adrian Foltyn, Former Head/Director of Data Science at HelloFresh, the online food survival kit provider, will take to the stage within the Data & Analytics for AI & IoT track on the 27 June at 15.20pm. Adrian will discuss why preference data is at the core of the company’s operations as their predictive technologies forecast the food that their consumers want during certain seasons.
5. AI and Computer Vision – Intelligent Assistants and an extra pair of eyes…
Join Miriam Huijser, Co-Founder & Chief Research Officer at Aiir Innovations on 28 June within the AI Technologies conference track as she explores how intelligence assistants can be used to inspect aircraft engines using state-of-the-art computer vision techniques. Aiir Innovations is an Amsterdam based start-up that aims to bring artificial intelligence to the maintenance and aircraft industry. They will also be exhibiting within the start-up incubator zone within the expo floor.
6. 2 co-located events
Co-located with the IoT Tech Expo and the Blockchain Expo, the AI Exhibition and Conference will allow you to explore 3 ecosystems in 1 and discover how the convergence of these 3 areas is powering the future of technology!
7. Using Big Data to create intelligent data models
Within the dedicated Data Analytics for AI & IoT track on the 27 June at 14.40pm, join AI & IoT thought leaders as they take to the stage for a panel discussion. Hear from Christophe Eschenbrenner, IoT & Data Foundations Program Manager from Alstom Digital Mobility, Violeta Misheva, Data Scientist at ABN AMRO Bank N.V., Filippo F.G. Della Casa, Head of Analytics at Unipol and Dor Kedem, Senior Data Scientist at ING as they discuss the increased need for big data analytics to drive AI & Machine Learning across a range of industries.
Other event features include exclusive networking opportunities
Following the first day of the event, Speakers, Sponsors, Press, Ultimate, Gold and Expo Plus attendees are invited to attend an evening of networking.
The Beach House will host the official networking party. It is located at the entrance of The Beach and surrounded by stunning beach scenery. Set away from the busier main structures and with its own bar and terrace. Discuss the topics from the conferences and build relationships with like-minded companies and individuals.
To register for your networking (Ultimate/ Gold/ Expo Plus) pass, click here.
The final advance rate ends 15 June so if you are looking for full conference and networking access, you can save up to €150 on your conference and networking pass (Gold/Ultimate) when you book by then.
You can find out more about the World Series 2018 and register for each event here:
AI Expo Europe – 27-28 th June 2018, RAI, Amsterdam
AI Expo North America – 28-29 th November 2018, Santa Clara, Silicon Valley
AI Expo Global – 25-26 th April 2019, Olympia Grand, London
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an